nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2022-9-4-81-87nodgo-886Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSЛучевой дерматит: современные представления о патогенезе, принципах профилактики и леченияRadiation dermatitis: current view on pathogenesis, principles of profilaxis and treatmenthttps://orcid.org/0000-0001-5911-553XБелышеваТ. С.BelyshevaT. S.

Татьяна Сергеевна Белышева, д. м. н., ведущий научный сотрудник

НИИ детской онкологии и гематологии

научно-консультативное отделение

115478

Каширское шоссе, 23

Москва

Dr. of Sci. (Med.), Leading Researcher

Research Institute of Pediatric Oncology and Hematology

Scientific Advisory Division

115478

23 Kashirskoe Shosse

Moscow

klinderma@bk.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

д. м. н., заведующий отделением

НИИ детской онкологии и гематологии

отделение детской онкологии и гематологии (химиотерапия гемобластозов) № 1

115478

Каширское шоссе, 23

Москва

Dr. of Sci. (Med.), Head of the Department

Research Institute of Pediatric Oncology and Hematology

Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1

115478

23 Kashirskoe Shosse

Moscow

timurvaliev@mail.ruhttps://orcid.org/0000-0002-0238-6563ШатохинаЕ. А.ShatokhinaE. A.

д. м. н., профессор

кафедра дерматовенерологии и косметологии

121359

ул. Маршала Тимошенко, 19, стр. 1А

119192

Ломоносовский просп., 27, корп. 10

Москва

Dr. of Sci. (Med.), Professor of Department, Senior Fellow

Dermatovenerology and Cosmetology Department

121359

Bld. 1A, 19 Marshala Timoshenko St.

Internal Medicine Department

119991

Bld. 10, 27 Lomonosovsky Prosp.

Moscow

e.a.shatokhina@gmail.comhttps://orcid.org/0000-0002-2391-4142ГригоренкоВ. А.GrigorenkoV. A.

врач-радиотерапевт, заведующий отделением

НИИ детской онкологии и гематологии

радиологическое отделение

115478

Каширское шоссе, 23

Москва

Radiotherapist, Head of the Department

Research Institute of Pediatric Oncology and Hematology

Radiological Department 

115478

23 Kashirskoe Shosse

Moscow

oncogrigorenko@yandex.ruhttps://orcid.org/0000-0001-6888-4760ПолонскаяА. С.PolonskayaA. S.

ассистент

кафедра дерматовенерологии и косметологии

121359

ул. Маршала Тимошенко, 19, стр. 1А

Москва

Assistant

Dermatovenerology and Cosmetology Department

121359

Bld. 1A, 19 Marshala Timoshenko St.

Moscow

dr.polonskaia@gmail.comhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

к. м. н., заместитель директора по научной и образовательной работе

НИИ детской онкологии и гематологии

115478

Каширское шоссе, 23

Москва

Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work

Research Institute of Pediatric Oncology and Hematology

115478

23 Kashirskoe Shosse

Moscow

k.kirgizov@ronc.ruhttps://orcid.org/0000-0001-6131-1783ВарфоломееваС. Р.VarfolomeevaS. R.

д. м. н., профессор, директор

НИИ детской онкологии и гематологии

115478

Каширское шоссе, 23

Москва

Dr. of Sci. (Med.), Professor, Director

Research Institute of Pediatric Oncology and Hematology

115478

23 Kashirskoe Shosse

Moscow

s.varfolomeeva@ronc.ruФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации; Медицинский научно-образовательный центр Московского государственного университета имени М. В. ЛомоносоваРоссияCentral State Medical Academy Department for Presidential Affairs of the Russian Federation; Medical Research and Educational Center at the Lomonosov Moscow State UniversityRussian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy Department for Presidential Affairs of the Russian FederationRussian Federation202203022023948187Copyright © Белышева Т.С., Валиев Т.Т., Шатохина Е.А., Григоренко В.А., Полонская А.С., Киргизов К.И., Варфоломеева С.Р., 20232023Белышева Т.С., Валиев Т.Т., Шатохина Е.А., Григоренко В.А., Полонская А.С., Киргизов К.И., Варфоломеева С.Р.Belysheva T.S., Valiev T.T., Shatokhina E.A., Grigorenko V.A., Polonskaya A.S., Kirgizov K.I., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/886

   При проведении лучевой терапии (ЛТ) отмечается высокая частота дерматологических нежелательных явлений. Лучевой дерматит является основным побочным эффектом со стороны кожи при проведении ЛТ. В статье рассмотрены современные представления о патогенезе лучевого дерматита, актуальные подходы к профилактике и лечению данного нежелательного явления.

   Radiation therapy (RT) is associated with high incidence of dermatologic adverse events. Radiation dermatitis is a major cutaneous side effect of RT. The article presents current views on pathogenesis of radiation dermatitis and modern approaches to prophylaxis and treatment of this cutaneous reaction.

лучевая терапияосложнениялучевой дерматитпрофилактикаподдерживающая терапияradiation therapyadverse eventsradiation dermatitisprophylaxissupportive therapyИсследование проведено без спонсорской поддержкиThe study was performed without external fundingReferencesLacouture M. E. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons, 2014.Lacouture M. E. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons, 2014.Salvo N., Barnes E., van Draanen J., Stacey E., Mitera G., Breen D., Giotis A., Czarnota G., Pang J., De Angelis C. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17 (4): 94–112. doi: 10.3747/co.v17i4.493.Salvo N., Barnes E., van Draanen J., Stacey E., Mitera G., Breen D., Giotis A., Czarnota G., Pang J., De Angelis C. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17 (4): 94–112. doi: 10.3747/co.v17i4.493.Janko M., Ontiveros F., Fitzgerald T. J., Deng A., DeCicco M., Rock K. L. IL-1 generated subsequent to radiation-induced tissue injury contributes to the pathogenesis of radiodermatitis. Radiat Res. 2012; 178 (3): 166–72. doi: 10.1667/rr3097.1.Janko M., Ontiveros F., Fitzgerald T. J., Deng A., DeCicco M., Rock K. L. IL-1 generated subsequent to radiation-induced tissue injury contributes to the pathogenesis of radiodermatitis. Radiat Res. 2012; 178 (3): 166–72. doi: 10.1667/rr3097.1.Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011; 11 (3): 213–20. doi: 10.1038/nri2936.Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011; 11 (3): 213–20. doi: 10.1038/nri2936.Allam R., Lawlor K. E., Yu E. C. Mitochondrial apoptosis is dispensable for NLRP3 infl ammasome activation but non-apoptotic caspase-8 is required for infl ammasome priming. EMBO Rep. 2014; 15 (9): 982–90. doi: 10.15252/embr.201438463.Allam R., Lawlor K. E., Yu E. C. Mitochondrial apoptosis is dispensable for NLRP3 infl ammasome activation but non-apoptotic caspase-8 is required for infl ammasome priming. EMBO Rep. 2014; 15 (9): 982–90. doi: 10.15252/embr.201438463.Pohlers D., Brenmoehl J., Löffler I. TGF-beta and fibrosis in diff erent organs – molecular pathway imprints. Biochim Biophys Acta. 2009; 1792 (8): 746–56. doi: 10.1016/j.bbadis.2009.06.004.Pohlers D., Brenmoehl J., Löffler I. TGF-beta and fibrosis in diff erent organs – molecular pathway imprints. Biochim Biophys Acta. 2009; 1792 (8): 746–56. doi: 10.1016/j.bbadis.2009.06.004.Flanders K. C. Smad 3 as a mediator of the fi brotic response. Int J Exp Pathol. 2004; 85 (2): 47–64. doi: 10.1111/j.0959-9673.2004.00377.x.Flanders K. C. Smad 3 as a mediator of the fi brotic response. Int J Exp Pathol. 2004; 85 (2): 47–64. doi: 10.1111/j.0959-9673.2004.00377.x.Martin D. J., Garske J. P., Davis M. K. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol. 2000; 68 (3): 438–50. PMID: 10883561.Martin D. J., Garske J. P., Davis M. K. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol. 2000; 68 (3): 438–50. PMID: 10883561.Vorotnikova E., Rosenthal R. A., Tries M., Doctrow S. R., Braunhut S. J. Novel synthetic SOD / catalase mimetics can mitigate capillary endothelial cell apoptosis caused by ionizing radiation. Radiat Res. 2010; 173 (6): 748–59. doi: 10.1667/RR1948.1.Vorotnikova E., Rosenthal R. A., Tries M., Doctrow S. R., Braunhut S. J. Novel synthetic SOD / catalase mimetics can mitigate capillary endothelial cell apoptosis caused by ionizing radiation. Radiat Res. 2010; 173 (6): 748–59. doi: 10.1667/RR1948.1.Dent P., Yacoub A., Fisher P. B., Hagan M. P., Grant S. MAPK pathways in radiation responses. Oncogene. 2003; 22 (37): 5885–96. doi: 10.1038/sj.onc.1206701.Dent P., Yacoub A., Fisher P. B., Hagan M. P., Grant S. MAPK pathways in radiation responses. Oncogene. 2003; 22 (37): 5885–96. doi: 10.1038/sj.onc.1206701.Drummond G. R., Selemidis S., Griendling K. K., Sobey C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011; 10 (6): 453–71. doi: 10.1038/nrd3403.Drummond G. R., Selemidis S., Griendling K. K., Sobey C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011; 10 (6): 453–71. doi: 10.1038/nrd3403.Panday A., Sahoo M. K., Osorio D., Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2015; 12 (1): 5–23. doi: 10.1038/cmi.2014.89.Panday A., Sahoo M. K., Osorio D., Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2015; 12 (1): 5–23. doi: 10.1038/cmi.2014.89.Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004; 75 (6): 639–53. doi: 10.1016/j.lfs.2003.10.042.Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004; 75 (6): 639–53. doi: 10.1016/j.lfs.2003.10.042.Ohta S., Matsuda S., Gunji M., Kamogawa A. The role of nitric oxide in radiation damage. Biol Pharm Bull. 2007; 30 (6): 1102–7. doi: 10.1248/bpb.30.1102.Ohta S., Matsuda S., Gunji M., Kamogawa A. The role of nitric oxide in radiation damage. Biol Pharm Bull. 2007; 30 (6): 1102–7. doi: 10.1248/bpb.30.1102.Frey B., Rückert M., Deloch L. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of infl ammatory diseases. Immunol Rev. 2017; 280 (1): 231–48. doi: 10.1111/imr.12572.Frey B., Rückert M., Deloch L. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of infl ammatory diseases. Immunol Rev. 2017; 280 (1): 231–48. doi: 10.1111/imr.12572.Yahyapour R., Amini P., Rezapoor S. Targeting of Infl ammation for Radiation Protection and Mitigation. Curr Mol Pharmacol. 2018; 11 (3): 203–10. doi: 10.2174/1874467210666171108165641.Yahyapour R., Amini P., Rezapoor S. Targeting of Infl ammation for Radiation Protection and Mitigation. Curr Mol Pharmacol. 2018; 11 (3): 203–10. doi: 10.2174/1874467210666171108165641.Gorski D. H., Beckett M. A., Jaskowiak N. T. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59 (14): 3374–8. PMID: 10416597.Gorski D. H., Beckett M. A., Jaskowiak N. T. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59 (14): 3374–8. PMID: 10416597.Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64 (11): 3731–6. doi: 10.1158/0008-5472.CAN-04-0074.Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64 (11): 3731–6. doi: 10.1158/0008-5472.CAN-04-0074.Wendt T. G., Grabenbauer G. G., Rödel C. M. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16 (4): 1318–24. doi: 10.1200/JCO.1998.16.4.1318.Wendt T. G., Grabenbauer G. G., Rödel C. M. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16 (4): 1318–24. doi: 10.1200/JCO.1998.16.4.1318.Swift M., Morrell D., Cromartie E., Chamberlin A. R., Skolnick M. H., Bishop D. T. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986; 39 (5): 573–83. PMID: 3788973.Swift M., Morrell D., Cromartie E., Chamberlin A. R., Skolnick M. H., Bishop D. T. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986; 39 (5): 573–83. PMID: 3788973.Iannuzzi C. M., Atencio D. P., Green S., Stock R. G., Rosenstein B. S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002; 52 (3): 606–13. doi: 10.1016/s0360-3016(01)02684-0.Iannuzzi C. M., Atencio D. P., Green S., Stock R. G., Rosenstein B. S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002; 52 (3): 606–13. doi: 10.1016/s0360-3016(01)02684-0.Meghrajani C. F., Co H. C., Ang-Tiu C. M., Roa F. C. Topical corticosteroid therapy for the prevention of acute radiation dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2013; 6 (6): 641–9. doi: 10.1586/17512433.2013.841079.Meghrajani C. F., Co H. C., Ang-Tiu C. M., Roa F. C. Topical corticosteroid therapy for the prevention of acute radiation dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2013; 6 (6): 641–9. doi: 10.1586/17512433.2013.841079.McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006; 22 (3): 163–73. doi: 10.1016/j.soncn.2006.04.004.McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006; 22 (3): 163–73. doi: 10.1016/j.soncn.2006.04.004.Frederick D. M., Renato G. P. Radiobiology and radiation effects. In: Wolff K., Goldsmith L. A., Katz S. I., Gilchrest B. A., Paller A. S., Leffell D. J., eds. Fitzpatrick’s dermatology in general medicine. 7<sup>th</sup> ed. New York: McGraw-Hill, 2008. Pp. 858–862.Frederick D. M., Renato G. P. Radiobiology and radiation effects. In: Wolff K., Goldsmith L. A., Katz S. I., Gilchrest B. A., Paller A. S., Leffell D. J., eds. Fitzpatrick’s dermatology in general medicine. 7<sup>th</sup> ed. New York: McGraw-Hill, 2008. Pp. 858–862.Bray F. N., Simmons B. J., Wolfson A. H., Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb). 2016; 6 (2): 185–206. doi: 10.1007/s13555-016-0120-y.Bray F. N., Simmons B. J., Wolfson A. H., Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb). 2016; 6 (2): 185–206. doi: 10.1007/s13555-016-0120-y.Bernier J., Domenge C., Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350 (19): 1945–52. doi: 10.1056/NEJMoa032641.Bernier J., Domenge C., Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350 (19): 1945–52. doi: 10.1056/NEJMoa032641.Madison K. C. Barrier function of the skin: “la raison d'être” of the epidermis. J Invest Dermatol. 2003; 121 (2): 231–41. doi: 10.1046/j.1523-1747.2003.12359.x.Madison K. C. Barrier function of the skin: “la raison d'être” of the epidermis. J Invest Dermatol. 2003; 121 (2): 231–41. doi: 10.1046/j.1523-1747.2003.12359.x.Porock D., Kristjanson L., Nikoletti S., Cameron F., Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum. 1998; 25 (6): 1019–29. PMID: 9679261.Porock D., Kristjanson L., Nikoletti S., Cameron F., Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum. 1998; 25 (6): 1019–29. PMID: 9679261.Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360-3016(95)00060-C.Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360-3016(95)00060-C.Chan R. J., Webster J., Chung B., Marquart L., Ahmed M., Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014; 14: 53. doi:10.1186/1471-2407-14-53.Chan R. J., Webster J., Chung B., Marquart L., Ahmed M., Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014; 14: 53. doi:10.1186/1471-2407-14-53.Bolderston A., Lloyd N. S., Wong R. K., Holden L., Robb-Blenderman L.; Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006; 14 (8): 802–17. doi: 10.1007/s00520-006-0063-4.Bolderston A., Lloyd N. S., Wong R. K., Holden L., Robb-Blenderman L.; Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006; 14 (8): 802–17. doi: 10.1007/s00520-006-0063-4.Wong R. K., Bensadoun R. J., Boers-Doets C. B. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013; 21 (10): 2933–48. doi: 10.1007/s00520-013-1896-2.Wong R. K., Bensadoun R. J., Boers-Doets C. B. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013; 21 (10): 2933–48. doi: 10.1007/s00520-013-1896-2.Пономаренко Г. Н. Общая физиотерапия: учебник / Г. Н. Пономаренко. – 5-е изд., перераб. и доп. – М.: ГЭОТАР-Медиа, 2013. – 365 с.Ponomarenko G. N. General Physiotherapy: textbook. 5<sup>th</sup> ed., revised. and additional. M.: GEOTAR-Media, 2013. 365 p. (In Russ.)Elad S., Cheng K. K. F., Lalla R. V. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in Cancer. 2021; 127 (19): 3700]. Cancer. 2020; 126 (19): 4423–31. doi: 10.1002/cncr.33100.Elad S., Cheng K. K. F., Lalla R. V. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in Cancer. 2021; 127 (19): 3700]. Cancer. 2020; 126 (19): 4423–31. doi: 10.1002/cncr.33100.Tran T. N., Hoang M. V., Phan Q. A. Fractional epidermal grafting in combination with laser therapy as a novel approach in treating radiation dermatitis. Semin Cutan Med Surg. 2015; 34 (1): 42–7. doi: 10.12788/j.sder.2015.0141.Tran T. N., Hoang M. V., Phan Q. A. Fractional epidermal grafting in combination with laser therapy as a novel approach in treating radiation dermatitis. Semin Cutan Med Surg. 2015; 34 (1): 42–7. doi: 10.12788/j.sder.2015.0141.Saei S., Sahebnasagh A., Ghasemi A. Efficacy of sucralfate ointment in the prevention of acute proctitis in cancer patients: A randomized controlled clinical trial. Caspian J Intern Med. 2020; 11 (4): 410–8. doi: 10.22088/cjim.11.4.410.Saei S., Sahebnasagh A., Ghasemi A. Efficacy of sucralfate ointment in the prevention of acute proctitis in cancer patients: A randomized controlled clinical trial. Caspian J Intern Med. 2020; 11 (4): 410–8. doi: 10.22088/cjim.11.4.410.Kouvaris J. R., Kouloulias V. E., Plataniotis G. A., Kokakis J. D., Vlahos L. J. Topical granulocyte-macrophage colony-stimulating factor for radiation dermatitis of the vulva. Br J Dermatol. 2001; 144 (3): 646–7. doi: 10.1046/j.1365-2133.2001.04115.x.Kouvaris J. R., Kouloulias V. E., Plataniotis G. A., Kokakis J. D., Vlahos L. J. Topical granulocyte-macrophage colony-stimulating factor for radiation dermatitis of the vulva. Br J Dermatol. 2001; 144 (3): 646–7. doi: 10.1046/j.1365-2133.2001.04115.x.Dunst J., Semlin S., Pigorsch S., Müller A. C., Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 2000; 176 (9): 416–21. doi: 10.1007/pl00002350.Dunst J., Semlin S., Pigorsch S., Müller A. C., Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 2000; 176 (9): 416–21. doi: 10.1007/pl00002350.Viswanath L., Bindhu J., Krishnamurthy B., Suresh K. P. Granulocyte-Colony Stimulating Factor (G-CSF) accelerates healing of radiation induced moist desquamation of the skin. Klin Onkol. 2012; 25 (3): 199–205. PMID: 22724569.Viswanath L., Bindhu J., Krishnamurthy B., Suresh K. P. Granulocyte-Colony Stimulating Factor (G-CSF) accelerates healing of radiation induced moist desquamation of the skin. Klin Onkol. 2012; 25 (3): 199–205. PMID: 22724569.Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009) [Electronic resource: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf]. US Department of Health and Human Services; National Institute of Health, National Cancer Institute v.4.03. 2010.Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009) [Electronic resource: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf]. US Department of Health and Human Services; National Institute of Health, National Cancer Institute v.4.03. 2010.

The authors declare that there are no conflicts of interest present.